ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties
Open accessPublished version of a preprint
Abstract
Oncogenic tyrosine kinase fusions involving the anaplastic lymphoma kinase (ALK) are detected in numerous tumor types. Although more than 30 distinct 5′ fusion partner genes have been reported, treatment of ALK-rearranged cancers is decided without regard to which 5′ partner is present. There is little data addressing how the 5′ partner affects the biology of the fusion or responsiveness to ALK tyrosine kinase inhibitors (TKI). On the basis of the hypothesis that the 5′ partner influences the intrinsic properties of the fusion protein, cellular functions that impact oncogenic potential, and sensitivity to ALK TKIs, clonal 3T3 cell lines stably expressing seven different ALK fusion variants were generated. Biochemical and cellular assays were used to assess the efficacy of various ALK TKIs in clinical use, transformative phenotypes, and biochemical properties of each fusion. All seven ALK fusions induced focus formation and colonies in soft agar, albeit to varying degrees. IC50s were calculated for different ALK TKIs (crizotinib, ensartinib, alectinib, lorlatinib) and consistent differences (5–10 fold) in drug sensitivity were noted across the seven ALK fusions tested. Finally, biochemical analyses revealed negative correlations between kinase activity and protein stability. These results demonstrate that the 5′ fusion partner plays an important biological role that affects sensitivity to ALK TKIs. Implications: This study shows that the 5′ ALK fusion partner influences ALK TKI drug sensitivity. As many other kinase fusions are found in numerous cancers, often with overlapping fusion partners, these studies have ramifications for other kinase-driven malignancies. Mol Cancer Res; 16(11); 1724–36. ©2018 AACR.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The PRKAR1A-ALK fusion is less sensitive to first, second, and third generation ALK TKIs.
“For example, the PRKAR1A-ALK fusion was consistently demonstrated to be less sensitive to first, second and third generation ALK TKIs48.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · see citing works
Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824 · see citing works
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317 · see citing works
Pankov, R. G., & Yamada, K. M. (2002) · Journal of Cell Science · doi:10.1242/jcs.00059 · Cited by 1,956 · see citing works
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · see citing works
Self-citationGainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo‐Jack, I., Gadgeel, S. M., Schultz, K. R., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,158 · see citing works
cAMP-DEPENDENT PROTEIN KINASE: FRAMEWORK FOR A DIVERSE FAMILY OF REGULATORY ENZYMES
Taylor, S. S., Buechler, J. A., & Yonemoto, W. M. (1990) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.59.070190.004543 · Cited by 1,144 · see citing works
Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., Kondo, K. L., Linderman, D. J., Heasley, L. E., Franklin, W. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2906 · Cited by 1,064 · see citing works
Melnick, A. M., & Licht, J. D. (1999) · Blood · doi:10.1182/blood.v93.10.3167.410k44_3167_3215 · Cited by 1,024 · see citing works
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix‐Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 893 · see citing works
Drilon, A. E. D. C., Siena, S., Ou, S. I., Patel, M. R., Ahn, M., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 827 · see citing works
Takeuchi, K., Choi, Y. L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3248 · Cited by 717 · see citing works
Mossé, Y. P., Lim, M. S., Voss, S. D., Wilner, K. D., Ruffner, K. L., Laliberté, J., Rolland, D. C. M., Balis, F. M., Maris, J. M., Weigel, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70095-0 · Cited by 708 · see citing works
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Hallberg, B., & Palmer, R. H. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3580 · Cited by 643 · see citing works
Drilon, A. E. D. C., Rekhtman, N., Arcila, M. E., Wang, L., Ni, A., Albano, M., van Voorthuysen, M., Somwar, R., Smith, R. S., Montecalvo, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30562-9 · Cited by 489 · see citing works
Zou, H. Y., Friboulet, L., Kodack, D. P., Engstrom, L. D., Li, Q., West, M., Tang, R. W., Wang, H., Tsaparikos, K. E., Wang, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.010 · Cited by 473 · see citing works
Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
Lovly, C. M., Gupta, A. A., Lipson, D., Otto, G. A., Brennan, T., Chung, C. T. ‐., Borinstein, S. C., Ross, J. S., Stephens, P. J., Miller, V. A., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0377 · Cited by 456 · see citing works
Self-citationIdentification of Novel Isoforms of the EML4-ALK Transforming Gene in Non–Small Cell Lung Cancer
Choi, Y. L., Takeuchi, K., Soda, M., Inamura, K., Togashi, Y., Hatano, S., Enomoto, M., Hamada, T., Haruta, H., Watanabe, H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6158 · Cited by 439 · see citing works
Epithelioid Inflammatory Myofibroblastic Sarcoma
Mariño‐Enríquez, A., Wang, W., Roy, A., Lopez-Terrada, D. H., Lazar, A. J., Fletcher, C. D. �., Coffin, C. M., & Hornick, J. L. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318200cfd5 · Cited by 389 · see citing works
Lin, J. J., Zhu, V. W., Yoda, S., Yeap, B. Y., Schrock, A. B., Dagogo‐Jack, I., Jessop, N. A., Jiang, G. Y., Le, L. P., Gowen, K. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2294 · Cited by 347 · see citing works
Self-citationSplinter, D., Tanenbaum, M. E., Lindqvist, A., Jaarsma, D., Flotho, A., Yu, K. L., Grigoriev, I., Engelsma, D., Haasdijk, E. D., Keijzer, N., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000350 · Cited by 327 · see citing works
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. J. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 301 · see citing works
Tyrosine kinase gene rearrangements in epithelial malignancies
Shaw, A. T., Hsu, P. P., Awad, M. M., & Engelman, J. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3612 · Cited by 291 · see citing works
Hernández, L., Pinyol, M., Hernandez, S. F., Beà, S., Pulford, K. A. F., Rosenwald, A., Lamant, L., Falini, B., Ott, G., Mason, D. Y., et al. (1999) · Blood · doi:10.1182/blood.v94.9.3265 · Cited by 285 · see citing works
Yoshida, T., Oya, Y., Tanaka, K., Shimizu, J., Horio, Y., Kuroda, H., Sakao, Y., Hida, T., & Yatabe, Y. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8732 · Cited by 266 · see citing works
Recent Advances in Targeting ROS1 in Lung Cancer
Lin, J. J., & Shaw, A. T. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.08.002 · Cited by 262 · see citing works
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
Heuckmann, J. M., Balke‐Want, H., Malchers, F., Peifer, M., Sos, M. L., Koker, M., Meder, L., Lovly, C. M., Heukamp, L. C., Pao, W. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3260 · Cited by 261 · see citing works
Self-citationAlternative transcription initiation leads to expression of a novel ALK isoform in cancer
Wiesner, T., Lee, W., Obenauf, A. C., Ran, L., Murali, R., Zhang, Q. F., Wong, E. W. P., Hu, W., Scott, S. N., Shah, R. H., et al. (2015) · Nature · doi:10.1038/nature15258 · Cited by 248 · see citing works
Woo, C. G., Seo, S., Kim, S. W., Jang, S., Park, K. S., Song, J., Lee, B., Richards, M. W., Bayliss, R. W., Lee, D. H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw693 · Cited by 219 · see citing works
Lovly, C. M., Heuckmann, J. M., de Stanchina, E., Chen, H., Thomas, R. K., Liang, C., & Pao, W. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3879 · Cited by 217 · see citing works
Self-citationSang, J., Acquaviva, J., Friedland, J. C., Smith, D. L., Sequeira, M., Zhang, C., Jiang, Q., Xue, L., Lovly, C. M., Jimenez, J.-P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0440 · Cited by 207 · see citing works
Self-citationGreco, A., Mariani, C., Miranda, C., Lupas, A. N., Pagliardini, S., Pomati, M., & Pierotti, M. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.11.6118 · Cited by 197 · see citing works
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Lee, C. C., Jia, Y., Li, N., Sun, X., Ng, K., Ambing, E., Gao, M.-Y., Hua, S., Chen, C., Kim, S., et al. (2010) · Biochemical Journal · doi:10.1042/bj20100609 · Cited by 182 · see citing works
Horvath, A., Bertherat, J. Y., Groussin, L., Guillaud-Bataille, M., Tsang, K., Cazabat, L., Libé, R., Remmers, E. F., René-Corail, F., Faucz, F. R., et al. (2010) · Human Mutation · doi:10.1002/humu.21178 · Cited by 175 · see citing works
Kinoshita, K., Asoh, K., Furuichi, N., Ito, T., Kawada, H., Hara, S., Ohwada, J., Miyagi, T., Kobayashi, T., Takanashi, K., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.021 · Cited by 168 · see citing works
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer
Brewer, M. R., Yun, C., Lai, D., Lemmon, M. A., Eck, M. J., & Pao, W. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220050110 · Cited by 148 · see citing works
Structure of the Bcr-Abl oncoprotein oligomerization domain.
Zhao, X., Ghaffari, S., Lodish, H. F., Malashkevich, V. N., & Kim, P. S. (2002) · PubMed · doi:10.1038/nsb747 · Cited by 143 · see citing works
Armstrong, F., Duplantier, M.-M., Trempat, P., Hiéblot, C., Lamant, L., Espinos, E., Racaud‐Sultan, C., Allouche, M., Campo, E., Delsol, G., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207813 · Cited by 129 · see citing works
Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer
Ren, H., Tan, Z., Zhu, X., Crosby, K., Haack, H., Ren, J., Beausoleil, S. A., Moritz, A., Innocenti, G., Rush, A. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3931 · Cited by 123 · see citing works
TFG clusters COPII‐coated transport carriers and promotes early secretory pathway organization
Johnson, A. J., Bhattacharya, N., Hanna, M., Pennington, J. G., Schuh, A. L., Wang, L., Otegui, M. S., Stagg, S. M., & Audhya, A. (2015) · The EMBO Journal · doi:10.15252/embj.201489032 · Cited by 117 · see citing works
Richards, M. W., Law, E. W. P., Rennalls, L. P., Busacca, S., O’Regan, L., Fry, A. M., Fennell, D. A., & Bayliss, R. W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322892111 · Cited by 115 · see citing works
Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas
Hernández, L., Beà, S., Bellosillo, B., Pinyol, M., Falini, B., Carbone, A., Ott, G., Rosenwald, A., Fernández, A., Pulford, K. A. F., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62574-6 · Cited by 107 · see citing works
Beetz, C., Johnson, A., Schuh, A. L., Thakur, S., Varga, R.-E., Fothergill, T., Hertel, N., Bomba-Warczak, E., Thiele, H., Nürnberg, G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217197110 · Cited by 106 · see citing works
Chen, S.-T., & Lee, J. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.04.016 · Cited by 105 · see citing works
Identification of NTRK fusions in pediatric mesenchymal tumors
Pavlick, D. C., Schrock, A. B., Malicki, D. M., Stephens, P. J., Kuo, D. J., Ahn, H., Turpin, B. K., Allen, J. M., Rosenzweig, M. R., Badizadegan, K., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26433 · Cited by 105 · see citing works
Richards, M. W., O’Regan, L., Röth, D., Montgomery, J. M., Straube, A., Fry, A. M., & Bayliss, R. W. (2015) · Biochemical Journal · doi:10.1042/bj20150039 · Cited by 101 · see citing works
Eichenmüller, B., Everley, P. A., Palange, J., Lepley, D. M., & Suprenant, K. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106628200 · Cited by 74 · see citing works
Structural and Functional Analysis of the C-Terminal Domain of Nup358/RanBP2
Lin, D. H., Zimmermann, S., Stuwe, T., Stuwe, E., & Hoelz, A. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.01.021 · Cited by 70 · see citing works
Prinz, A., Diskar, M., Erlbruch, A., & Herberg, F. W. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.01.013 · Cited by 68 · see citing works
McFadden, D. G., Dias-Santagata, D. C., Sadow, P. M., Lynch, K. D., Lubitz, C. C., Donovan, S. E., Zheng, Z., Le, L. P., Iafrate, A. J., & Daniels, G. H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2611 · Cited by 67 · see citing works
Tognon, C. E., Mackereth, C. D., Somasiri, A. M., McIntosh, L. P., & Sorensen, P. H. B. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.11.4636-4650.2004 · Cited by 45 · see citing works
Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer
Ayeni, D. O., Politi, K. A., & Goldberg, S. B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1211 · Cited by 44 · see citing works
Baumann, H., Kunapuli, P., Tracy, E., & Cowell, J. K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300018200 · Cited by 43 · see citing works
A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK
Penzel, R., Schirmacher, P., & Warth, A. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182598af3 · Cited by 40 · see citing works
Identification of RANBP2–ALK fusion in ALK positive diffuse large B‐cell lymphoma
Lee, S. E., Kang, S. Y., Takeuchi, K., & Ko, Y. H. (2014) · Hematological Oncology · doi:10.1002/hon.2125 · Cited by 39 · see citing works
Detecting and targetting oncogenic fusion proteins in the genomic era
Davare, M. A., & Tognon, C. E. (2015) · Biology of the Cell · doi:10.1111/boc.201400096 · Cited by 37 · see citing works
Mazot, P., Cazes, A., Dingli, F., Degoutin, J. L., Irinopoulou, T., Boutterin, M., Lombard, B., Loew, D., Hallberg, B., Palmer, R. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033581 · Cited by 33 · see citing works
Evidence of TRK-Fused Gene (TFG1) function in the ubiquitin–proteasome system
Yagi, T., Ito, D., & Suzuki, N. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.02.011 · Cited by 24 · see citing works
Medves, S., Noël, L. A., Montano‐Almendras, C. P., Albu, R. I., Schoemans, H. M., Constantinescu, S. N., & Demoulin, J. (2011) · Haematologica · doi:10.3324/haematol.2011.040147 · Cited by 23 · see citing works
Oncogenic TPM3-ALK activation requires dimerization through the coiled-coil structure of TPM3
Amano, Y., Ishikawa, R., Sakatani, T., Ichinose, J., Sunohara, M., Watanabe, K., Kage, H., Nakajima, J., Nagase, T., Ohishi, N., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.014 · Cited by 22 · see citing works
Iadevaia, S., & Ram, P. T. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-4920 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019 · see citing works
Имянитов, Е. Н., Iyevleva, A. G., & Levchenko, E. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103194 · Cited by 528 · see citing works
Krook, M. A., Reeser, J. W., Ernst, G., Barker, H. D., Wilberding, M., Li, G., Chen, H., & Roychowdhury, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01157-0 · Cited by 369 · see citing works
Self-citationALK-positive lung cancer: a moving target
Schneider, J. L., Lin, J. J., & Shaw, A. T. (2023) · Nature Cancer · doi:10.1038/s43018-023-00515-0 · Cited by 190 · see citing works
Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules
Tulpule, A., Guan, J., Neel, D. S., Allegakoen, H. R., Lin, Y. P., Brown, D., Chou, Y.-T., Heslin, A., Chatterjee, N., Perati, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.031 · Cited by 189 · see citing works
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 153 · see citing works
Variant classification in precision oncology
Leichsenring, J., Horak, P., Kreutzfeldt, S., Heining, C., Christopoulos, P., Volckmar, A., Neumann, O., Kirchner, M., Ploeger, C., Budczies, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32358 · Cited by 130 · see citing works
What do we know about inflammatory myofibroblastic tumors? – A systematic review
Siemion, K., Reszeć-Giełażyn, J., Kiśluk, J., Roszkowiak, Ł., Żak, J., & Korzyńska, A. (2022) · Advances in Medical Sciences · doi:10.1016/j.advms.2022.02.002 · Cited by 124 · see citing works
Zhang, S. S., Nagasaka, M., Zhu, V. W., & Ou, S. I. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.012 · Cited by 114 · see citing works
Mahajan, P., Casanova, M., Ferrari, A., Fordham, A. M., Trahair, T. N., & Venkatramani, R. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100768 · Cited by 85 · see citing works
Inflammatory Myofibroblastic Tumor: An Updated Review
Choi, J. H. (2025) · Cancers · doi:10.3390/cancers17081327 · Cited by 73 · see citing works
Lopez‐Nunez, O. F., John, I., Panasiti, R. N., Ranganathan, S., Santoro, L., Grélaud, D., Wu, T., Buccoliero, A. M., Casanova, M., Alaggio, R., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0406-6 · Cited by 63 · see citing works
Lin, J. J., Horan, J. C., Tangpeerachaikul, A., Swalduz, A., Valdivia, A., Johnson, M. L., Besse, B., Camidge, D. R., Fujino, T., Yoda, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0231 · Cited by 62 · see citing works
CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome
Ou, S. I., & Zhu, V. W. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.025 · Cited by 55 · see citing works
The oncogenic fusion landscape in pediatric CNS neoplasms
Roosen, M. M., Odé, Z., Bunt, J., & Kool, M. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02405-8 · Cited by 52 · see citing works
Improved Gene Fusion Detection in Childhood Cancer Diagnostics Using RNA Sequencing
Hehir-Kwa, J. Y., Koudijs, M. J., Verwiel, E. T. P., Kester, L. A., van Tuil, M., Strengman, E., Buijs, A., Kranendonk, M. E. G., Hiemcke‐Jiwa, L. S., de Haas, V., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.20.00504 · Cited by 48 · see citing works
ALK in cancer: from function to therapeutic targeting
Voena, C., Ambrogio, C., Iannelli, F., & Chiarle, R. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00797-9 · Cited by 45 · see citing works
Clinically relevant fusion oncogenes: detection and practical implications
Sorokin, M., Rabushko, E., Rozenberg, J. M., Mohammad, T., Seryakov, A., Sekacheva, M. I., & Buzdin, A. A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221144108 · Cited by 37 · see citing works
Tian, P., Liu, Y., Zeng, H., Tang, Y., Lizaso, A., Ye, J., Shao, L., & Li, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03116-6 · Cited by 32 · see citing works
Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment
Vilachã, J. F., Mitchel, S. C., Akele, M. Z., Evans, S., & Groves, M. R. (2020) · Crystals · doi:10.3390/cryst10090725 · Cited by 29 · see citing works
Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion
Bennett, J. A., Wang, P., Wanjari, P., Díaz, L., & Oliva, E. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22986 · Cited by 30 · see citing works
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
Tabbò, F., Reale, M. L., Bironzo, P., & Scagliotti, G. V. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-372 · Cited by 29 · see citing works
Fukui, T., TACHIHARA, M. Y., Nagano, T., & Kobayashi, K. (2022) · Cancers · doi:10.3390/cancers14051184 · Cited by 30 · see citing works
Reinhart, S., Trachsel, Y., Fritz, C., Wagner, U., Bode‐Lesniewska, B., John, H. A., & Pless, M. (2020) · Urology · doi:10.1016/j.urology.2020.09.026 · Cited by 28 · see citing works
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression
Chuang, T., Lai, W., Gabre, J. L., Lind, D. E., Umapathy, G., Bokhari, A. A., Bergman, B., Kristenson, L., Thorén, F. B., Le, A. T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2216479120 · Cited by 28 · see citing works
Chen, H., Wang, W., Xu, C., Huang, L., Li, X., Lan, G., Zhai, Z., Zhu, Y., Du, K., Lei, L., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.012 · Cited by 27 · see citing works
Self-citationClinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions
Mondaca, S., Lebow, E. S., Namakydoust, A., Razavi, P., Reis-Filho, J. S., Shen, R., Offin, M. D., Tu, H., Murciano‐Goroff, Y. R., Xu, C., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.018 · Cited by 26 · see citing works
Li, M., An, Z., Tang, Q., Ma, Y., Yan, J., Chen, S., & Wang, Y. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16897 · Cited by 25 · see citing works
Peng, Y., Zhao, Q., Liao, Z., Ma, Y., & Ma, D. (2023) · Cancer · doi:10.1002/cncr.34664 · Cited by 23 · see citing works
Li, W., Fei, K., Guo, L., Wang, Y., Shu, C., Wang, J., & Ying, J. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.12.009 · Cited by 20 · see citing works
Karachaliou, N., Bruno, M. F., Bracht, J. W. P., & Rosell, R. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s174548 · Cited by 18 · see citing works
Murumägi, A., Ungureanu, D., Arjama, M., Bützow, R. C., Lohi, J., Sariola, H. V., Kanerva, J. A., Koskenvuo, M., & Kallioniemi, O. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101027 · Cited by 18 · see citing works
Wang, M., Slatter, S., Sussell, J. A., Lin, C.-W., Ogale, S. S., Datta, D., Butte, A. J., Bazhenova, L. A., & Rudrapatna, V. A. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00973-7 · Cited by 18 · see citing works
Hunt, A. L., Nutcharoen, A., Randall, J., Papazian, A., Deeken, J. F., Maxwell, G. L., Bateman, N. W., Petricoin, E. F., Benyounes, A., Conrads, T. P., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad129 · Cited by 17 · see citing works
Low prevalence of HTLV-II in Mayan Indians in the Yucatan Peninsula, Mexico.
Góngora-Biachi, R. A., Lal, R. B., Rudolph, D. L., Castro-Sansores, C. J., González-Martínez, P. M., & Pavía‐Ruz, N. (1997) · PubMed · Cited by 16 · see citing works
Ferreira, D., Miranda, J., Martins‐Lopes, P., Adega, F., & Chaves, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083815 · Cited by 15 · see citing works
Singh, P., Nambirajan, A., Gaur, M. K., Raj, R., Kumar, S., Malik, P. S., & Jain, D. (2022) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2022.05.08 · Cited by 15 · see citing works
Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion
Ren, H., Hou, X., Eiken, P. W., Zhang, J., Pierson, K. E., Nair, A., Davila, J. I., Kovaříková, H., Jang, J. S., Johnson, S. H., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.002 · Cited by 14 · see citing works
Case Report: RAB10-ALK: A Novel ALK Fusion in a Patient With Gastric Cancer
Wen, Z., Xiong, D., Zhang, S., Liu, J., Li, B., Li, R., & Zhang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.645370 · Cited by 14 · see citing works
Zhang, L., Xiao, P., Meng, F., & Zhong, D. (2022) · Current Oncology · doi:10.3390/curroncol29100530 · Cited by 12 · see citing works
Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?
Tabbò, F., Passiglia, F., & Novello, S. (2021) · Current Oncology Reports · doi:10.1007/s11912-020-00989-6 · Cited by 12 · see citing works
Targeting SLMAP-ALK—a novel gene fusion in lung adenocarcinomaPreprint
Pagan, C. A., Barua, S., Hsiao, S. J., MANSUKHANI, M. M., Saqi, A., Murty, V. V. V. S., & Fernandes, H. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003939 · Cited by 12 · see citing works
ALK Inhibitors-Induced M Phase Delay Contributes to the Suppression of Cell Proliferation
Munira, S., Yuki, R., Saito, Y., & Nakayama, Y. (2020) · Cancers · doi:10.3390/cancers12041054 · Cited by 11 · see citing works
Fujiki, T., Sakai, Y., Ikawa, Y., Takenaka, M., Noguchi, K., Kuroda, R., Abe, T., Nomura, K., Sakai, S., & Wada, T. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30172 · Cited by 11 · see citing works
Hu, T., Zhan, J., Li, L., He, Y., Lin, Y., Wang, J., Yu, H., Xiong, J., Fang, Z., Deng, J., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae020 · Cited by 11 · see citing works
Sánchez‐Herrero, E., Campos‐Silva, C., Cáceres‐Martell, Y., de Lope, L. R., Sanz‐Moreno, S., Serna‐Blasco, R., Rodríguez-Festa, A., Trotta, D. A., Martín, P., Patiño, C., et al. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac021 · Cited by 10 · see citing works
Tao, H., Liu, Z., Mu, J., Gai, F., Huang, Z., & Shi, L. (2022) · Diagnostic Pathology · doi:10.1186/s13000-022-01212-9 · Cited by 10 · see citing works
Li, Y., Duan, P., Guan, Y., Chen, Q., Grenda, A., Christopoulos, P., Denis, M. G., & Guo, Q. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-1039 · Cited by 10 · see citing works
Heterogeneity in MET-Aberrant NSCLC
Le, X. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1609 · Cited by 10 · see citing works
He, Z., Wu, X., Ma, S., Zhang, C., Zhang, Z., Wang, S., Yu, S., & Wang, Q. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.001 · Cited by 9 · see citing works
Wu, J., Hu, Y., Abdihamid, O., Huang, G., Xiao, S., & Li, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684865 · Cited by 9 · see citing works
EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Diaz-Jimenez, A., Shuldiner, E. G., Somogyi, K., Shih, K. Y., González-Velasco, Ó., Najajreh, M., Kim, S. J., Akkas, F., Murray, C. W., Andrejka, L., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1417 · Cited by 8 · see citing works
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications
Seker‐Cin, H., Tay, T. K. Y., Kazdal, D. N., Kluck, K., Ball, M., Neumann, O., Winter, H., Herth, F. J. F., Heußel, C. P., Savai, R., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107317 · Cited by 8 · see citing works
Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors
Valéry, M., Facchinetti, F., Malka, D., Ducreux, M. P., Friboulet, L., & Hollebecque, A. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.09.001 · Cited by 8 · see citing works
Garinet, S., Mansuet‐Lupo, A., Denize, T., Loyaux, R., Timsit, S., Gazeau, B., Fabre, E., Maaradji, Z., Gibault, L., Leprieur, E. G., et al. (2024) · Pathology · doi:10.1016/j.pathol.2024.02.014 · Cited by 7 · see citing works
Li, H., Liu, J., Lan, S., Zhong, R., Cui, Y., Christopoulos, P., Schenk, E. L., Sasaki, T., & Cheng, Y. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-656 · Cited by 6 · see citing works
Chayab, L., Leighl, N. B., Tadrous, M., Warren, C. M., & Wong, W. W. L. (2024) · Current Oncology · doi:10.3390/curroncol32010013 · Cited by 6 · see citing works
[A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene].
Yuan, Y., Wang, Z., Nie, X., Zhang, P., & Lin, L. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.29 · Cited by 6 · see citing works
Lorlatinib for the Treatment of ALK Fusion–Positive Infant-Type Hemispheric Glioma: A Case Report
Greenwell, A. M., Baughan, S. L., Altınok, D., Marupudi, N. I., Kupsky, W. J., Kumar‐Sinha, C., & Gorsi, H. S. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00255 · Cited by 6 · see citing works
Wagener‐Ryczek, S., & Pappesch, R. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1920399 · Cited by 6 · see citing works
Chung, C., & Umoru, G. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241242684 · Cited by 5 · see citing works
Oncogenic signaling of RTK fusions becomes more granular
Cuneo, M. J., & Mittag, T. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.05.029 · Cited by 5 · see citing works
Sica, A., Sagnelli, C., Casale, B., Svanera, G., Creta, M., Calogero, A., Franco, R., Sagnelli, E., & Ronchi, A. (2021) · Healthcare · doi:10.3390/healthcare9020135 · Cited by 5 · see citing works
Du, J., Wang, B., Li, M., Wang, C., Ma, T., & Shan, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.898954 · Cited by 5 · see citing works
Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report
Lin, J., Wang, W., Lin, J., Chen, R., & Cao, Y. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17520 · Cited by 5 · see citing works
Inflammatory myofibroblastic tumor of the urinary bladder with FN1‑ALK gene fusion: A case report
Son, S.-M., Woo, C. G., Lee, O.-J., Kim, Y., & Lee, H. (2023) · Oncology Letters · doi:10.3892/ol.2023.13813 · Cited by 5 · see citing works
Urbanska, E. M., Koffeldt, P. R., Grauslund, M., Melchior, L. C., Sørensen, J. B., & Santoni‐Rugiu, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26135969 · Cited by 4 · see citing works
Agnostic drug development revisited
Hernando‐Calvo, A., Rossi, A., Vieito, M., Voest, E. E., & Garralda, E. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102747 · Cited by 4 · see citing works
Recurrent Inflammatory Myofibroblastic Tumor of Larynx Harboring a Novel THBS1::ALK Fusion
Ajmal, N., Gargano, S., Gosavi, U., & Tuluc, M. (2024) · International Journal of Genomics · doi:10.1155/2024/4937501 · Cited by 4 · see citing works
Frederico, I. K. S., Ardakani, N. M., Ryan, A. L., Cowley, M. J., & Wood, B. A. (2021) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001972 · Cited by 4 · see citing works
Itchins, M., & Pavlakis, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.959637 · Cited by 4 · see citing works
Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report
Zhou, H., Xu, B., Xu, J.-L., Zhu, G., & Guo, Y. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670907 · Cited by 4 · see citing works
Muratcioğlu, S., Eide, C. A., Hung, C., Gorday, K., Sumpena, E., Zuo, W., Groves, J. T., Druker, B. J., & Kuriyan, J. (2025) · Science Signaling · doi:10.1126/scisignal.adt5931 · Cited by 3 · see citing works
LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report
Yang, Y., Zheng, H., Li, Z., Shi, S., Zhong, L., Gong, L., & Lan, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.841493 · Cited by 3 · see citing works
Gilson, P., Pouget, C., Belmonte, R., Fadil, S., Demange, J., Rouyer, M., Lacour, J., Betz, M., Dardare, J., Witz, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39749-4 · Cited by 3 · see citing works
Mesquita, F. P., Lima, L. B., da Silva, E. L., Souza, P. F. N., de Moraes, M. E. A., Burbano, R. M. R., & Montenegro, R. C. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037291318240130103348 · Cited by 3 · see citing works
Pan, X., Zhong, A., Xing, Y., Li, X., Du, H., & Shi, M. (2021) · Journal of International Medical Research · doi:10.1177/03000605211044652 · Cited by 3 · see citing works
Zhang, B., Zhang, Y., Xu, J., Zhang, X., Chu, T., Wang, S., Qian, J., Qiao, R., Lü, J., Zhang, L., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0592-z · Cited by 3 · see citing works
Kakuta, R., Takemoto, A., Tanimoto, K., Noji, R., Kudo, R., Kano, Y., Ando, Y., Simoi, T., Kinugasa, Y., & Ikeda, S. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf056 · Cited by 2 · see citing works
Li, M., Shen, L. H., & Sun, X. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0330-x · Cited by 2 · see citing works
Chen, L., Chu, D., Li, W., & Zhang, H. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001531 · Cited by 2 · see citing works
Sorokin, M., Lyadov, V. K., Suntsova, M., Garipov, M. R., Semenova, A., Popova, N., Guguchkin, E., Heydarov, R. N., Zolotovskaia, M., Zhao, X., et al. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1448792 · Cited by 2 · see citing works
Ren, H., Cheng, Q., Chen, X., Sui, D., Zhang, Z., & Chen, F. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1481602 · Cited by 2 · see citing works
Pediatric Low-Grade Spindle Cell Neoplasm With A Novel AK5::ALK Fusion: A Case Report
Kikawa, C., Ketterl, T. G., Liu, Y. J., Reed, R. C., & Dahl, J. P. (2022) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894221092207 · Cited by 2 · see citing works
Chen, T.-W., Kuo, Y.-J., Lee, J., & Chen, C. (2020) · Journal of Cancer Research and Practice · doi:10.4103/jcrp.jcrp_25_20 · Cited by 2 · see citing works
Guan, J., Chuang, T., Vikström, A., Palmer, R. H., & Hallberg, B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1281510 · Cited by 1 · see citing works
ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report
Hsu, C., Yakoub, M. A., Offin, M. D., Eng, J., Drilon, A. E. D. C., & Yang, S. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100934 · Cited by 1 · see citing works
A case of STRN-ALK fusion positive lung adenocarcinoma treated with lorlatinib monotherapy
Hanna, C. S., Godin, S., Jones, J., Chang, Y., & Robinson, N. (2026) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2026.100411 · Cited by 1 · see citing works
Brisudová, A., & Škarda, J. (2020) · Biomedical Papers · doi:10.5507/bp.2020.015 · Cited by 1 · see citing works
The ALK receptor tyrosine kinase journey: From physiological roles to pathological disruptions
Tabbò, F., Righi, L., Taulli, R., & Novello, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821774-0.00010-3 · Cited by 1 · see citing works
Liu, Z., Wu, Q., Li, W., Li, P., Huang, L., Wang, T., & Zhou, Q. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107386 · Cited by 1 · see citing works
Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function
Yang, Q., Guo, Y., Guo, W., Liu, D., Wang, H., & Cai, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-92590-9 · Cited by 1 · see citing works
Xiao, S., Gui, Q., Zhang, Y., Yang, M., Liang, R., Huang, M., Yang, X., Chen, N., Chen, X., Wu, M., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6513808/v1 · Cited by 1 · see citing works
Self-citationAl-Mekhlafi, A.-W. A.-G. S., & Alashaari, G. A. A. (2021) · International Journal of ADVANCED AND APPLIED SCIENCES · doi:10.21833/ijaas.2021.04.003
Pang, D., Huang, L., Jiang, X., Chen, F., Guo, H., Wei, X., Liu, S., Teng, Y., Liang, Z., & Li, W. (2020) · doi:10.21203/rs.3.rs-39803/v1
Centonza, A., Mazza, T., Trombetta, D., Sparaneo, A., Petrizzelli, F., Castellana, S., Centra, F., Fabrizio, F. P., Micco, C. M. D., Benso, F., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070670
Muratcioğlu, S., Eide, C. A., Gorday, K., Sumpena, E., Zuo, W., Groves, J. T., Druker, B. J., & Kuriyan, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.02.616342
Lopez-Terrada, D. H., & Alaggio, R. (2024) · Springer eBooks · doi:10.1007/978-3-031-62589-3_14
Liang, Q., Li, N., & Li, X. (2024) · PubMed Central · doi:10.11817/j.issn.1672-7347.2024.230503
Translational transcriptomics for personalized oncology
Buzdin, A. A., Seryakov, A. P., Zolotovskaia, M., Sorokin, M., Tkachev, V., Giese, A., Sekacheva, M. I., Poddubskaya, E. V., Rozenberg, J. M., & Mohammad, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19110-7.00008-2
- Authors
- Childress, M. A., Himmelberg, S. M., Chen, H., Deng, W., Davies, M. A., & Lovly, C. M.
- Affiliations
- Vanderbilt University (US)
- Vanderbilt University Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Lovly, Christine M.
- Venue
- Molecular Cancer Research
- Published
- 2018-11-01
- Volume
- 16
- Issue
- 11
- Pages
- 1724-1736
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- PMC
- PMC6214753
- OpenAlex
- W2839057355
- Cited by
- 108
- References
- 61
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 13 · 2023: 14 · 2022: 17 · 2021: 20 · 2020: 12 · 2019: 10 · 2018: 2
- FWCI
- 8.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- For the Linds Foundation
- International Association for the Study of Lung Cancer (IASLC)
- HHS | NIH | National Cancer Institute (NCI) (CA009592, CA16672, R01CA121210, CA213744-02)
- TJ Martell Foundation
- American Cancer Society (ACS) (IRG-58-009-54)
- Damon Runyon Cancer Research Foundation (Damon Runyon)
- LUNGevity Foundation
- V Foundation for Cancer Research (V Foundation)
- AACR-Genentech Career Development Award (15-20-18-LOVL)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- ALK fusion partners, anaplastic lymphoma kinase, tyrosine kinase inhibitors, drug sensitivity, kinase activity, protein stability, crizotinib, ensartinib, alectinib, lorlatinib, oncogenic transformation, soft agar colony formation
- MeSH terms
- Anaplastic Lymphoma Kinase, Animals, Phenotype, Oncogene Proteins, Fusion, NIH 3T3 Cells, Cell Line, Tumor, Protein Kinase Inhibitors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
